Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
68.85
-0.11 (-0.16%)
Apr 25, 2025, 1:47 PM EDT - Market open
Insmed Employees
Insmed had 1,271 employees as of December 31, 2024. The number of employees increased by 359 or 39.36% compared to the previous year.
Employees
1,271
Change (1Y)
359
Growth (1Y)
39.36%
Revenue / Employee
$286,158
Profits / Employee
-$718,939
Market Cap
12.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,271 | 359 | 39.36% |
Dec 31, 2023 | 912 | 176 | 23.91% |
Dec 31, 2022 | 736 | 123 | 20.07% |
Dec 31, 2021 | 613 | 92 | 17.66% |
Dec 31, 2020 | 521 | 86 | 19.77% |
Dec 31, 2019 | 435 | 62 | 16.62% |
Dec 31, 2018 | 373 | 159 | 74.30% |
Dec 31, 2017 | 214 | 53 | 32.92% |
Dec 31, 2016 | 161 | 36 | 28.80% |
Dec 31, 2015 | 125 | 36 | 40.45% |
Dec 31, 2014 | 89 | 28 | 45.90% |
Dec 31, 2013 | 61 | 20 | 48.78% |
Dec 31, 2012 | 41 | -1 | -2.38% |
Dec 31, 2011 | 42 | 2 | 5.00% |
Dec 31, 2010 | 40 | 25 | 166.67% |
Dec 31, 2009 | 15 | -82 | -84.54% |
Dec 31, 2008 | 97 | 3 | 3.19% |
Dec 31, 2007 | 94 | -63 | -40.13% |
Dec 31, 2006 | 157 | 72 | 84.71% |
Dec 31, 2005 | 85 | 30 | 54.55% |
Dec 31, 2004 | 55 | 35 | 175.00% |
Dec 31, 2003 | 20 | -3 | -13.04% |
Dec 31, 2002 | 23 | -37 | -61.67% |
Dec 31, 2001 | 60 | 20 | 50.00% |
Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
INSM News
- 1 hour ago - Insmed: Poised For Transformation Beyond ARIKAYCE - Seeking Alpha
- 1 day ago - Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 - PRNewsWire
- 1 day ago - New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - PRNewsWire
- 2 days ago - Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 - PRNewsWire
- 4 weeks ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 4 weeks ago - Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference - PRNewsWire
- 6 weeks ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga